eliquis ( apixaban)

Apixaban is an antithrombotic drug that inhibits factor Xa, and hereby the development of thrombin as well as the formation of thromboses.

Apixaban is approved for prevention of venous thromboembolism (VTE) in adult patients, who are undergoing scheduled hip or knee alloplastic surgery.

As with other new oral antithrombotics, there is no need for surveillance of coagulation parameters, and apixaban  has, as well as dabigatran(link) and rivaroxaban(link,) a comparable effect and side effect profile (risk of bleeding) to that of low-molecular heparin, in relevant doses.

There are no therapeutic advantages of apicaban compared to dabigatran and rivaroxaban. Apixaban is administered 12-24 hours after an operation, dabigatran after 1-4 hours, and riveroxaban after 6-10 hours.

IRF finds, that apixaban is equal to low-molecular heparin, rivaroxaban and dabigatran. Dabigatran is at the moment somewhat cheaper than the others.

 

Edarbyclor
 

 

EDARBYCLOR (azilsartan medoxomil and chlorthalidone) 40/12.5mg, 40/25mg tablets by Takeda


 Edarbyclor (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension in adults. This approval was based on results from a clinical program consisting of five Phase 3 clinical studies involving more than 5,000 patients with hypertension. The studies demonstrated that Edarbyclor lowered mean trough (22–24 hours) systolic blood pressure by Ambulatory Blood Pressure Monitoring significantly more than either azilsartan medoxomil or chlorthalidone alone, lowered blood pressure in black and non-black patients at similar levels, and lowered clinic SBP significantly more than the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide at its highest approved dose (40/25mg doses for both medications).

Edarbyclor is a fixed-dose combination of an angiotensin II receptor blocker and diuretic. It will be available in 40/12.5mg and 40/25mg dosage strength tablets.


Ticagrelor (Brilinta^TM)

 
 

On July 20^th, the FDA approved Ticagrelor (Tradename: Brilinta; Research Code: AZD-6140), a purinergic receptor P2Y12 platelet antagonist indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
 

Acute coronary syndrome is often the initial presentation of an individual manifesting coronary artery disease (CAD). ACS can present as unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction. Typically, ACS begins with the rupture or erosion of a vulnerable plaque in a coronary artery, which results in the exposure of elements under the endothelial layer, such as collagen or von Willebrand factor, to circulating blood. These ligands trigger a series of responses, including platelet adhesion, activation, and aggregation.

 

 

 

EDARBİ( AZİLSARTAN)

Edarbi (azilsartan medoxomil tablets; Takeda Pharmaceuticals North America) has been approved by the FDA for the treatment of hypertension in adults. This approval was based on data from Phase 3 clinical trials which showed that Edarbi successfully met the primary endpoint, change in 24-hour mean systolic blood pressure (SBP), with statistical significance of lowering blood pressure compared to placebo and head-to-head active comparators. Results from one study showed Edarbi at doses of 80 mg/day and 40 mg/day lowered 24-hour mean SBP by 14.3mmHg and 13.2mmHg from baseline, respectively. The blood pressure reductions of Edarbi (80 mg/day) were statistically superior to those of the active comparators valsartan 320mg/day (-10mmHg) and olmesartan medoxomil 40mg/day (-11.7mmHg). Similar results were observed in all three comparator studies.   

Edarbi will be available in 40mg and 80mg dosage strengths.

AMTURNIDE

 

Pharmacological Class:

Renin inhibitor + dihydropyridine calcium channel blocker (CCB) + thiazide diuretic.

Active Ingredient(s):

Aliskiren hemifumarate/amlodipine besylate/hydrochlorothiazide (HCTZ); 150/5/12.5mg; 300/5/12.5mg; 300/5/25mg; 300/10/12.5mg; 300/10/25mg; tablets.

 

 

Indication(s):

Hypertension. Not for initial therapy.

TRİBENZOR( olmesartan+amlodipine) 

 

Indication

Manufacturer:

Daiichi Sankyo

Pharmacological Class:

Antihypertensive (angio­tensin 2 receptor blocker + dihydropyridine calcium channel blocker + thiazide diuretic).

Active Ingredient(s):

Olmesartan medoxomil 20mg, amlodipine (as besylate) 5mg, hydrochlorothiazide (HCTZ) 12.5mg; tabs.

Also:

Pharmacological Class:

Antihypertensive (direct renin inhibitor + angiotensin II receptor blocker)

Active Ingredient(s):

Aliskiren 150mg, valsartan 160mg; tabs.

Also:

 

Indication(s):

Hypertension, as monotherapy or with other antihypertensives. As initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.

 

VALTURNA 300mg/320mg
Aliskiren 300mg, valsartan 320mg; tabs.

TWYNSTA

Antihypertensive (angiotensin II receptor blocker + calcium channel blocker)

Active Ingredient(s):

Telmisartan 40mg, amlodipine 5mg; tabs.

Also: